It’s time to look ahead with the HAE treatment your child
TAKHZYRO—An established partner in your child’s HAE journey
With 12+ years of experience, Takeda is committed to families living with HAE
TAKHZYRO is the #1 prescribed HAE preventive treatment.* Here are a few reasons to consider it as an option for your child:
*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.
3,250+ adolescents and adults have been prescribed TAKHZYRO since 2018†
†Based on third-party US specialty pharmacy data.
Established safety profile in a 52-week study of 21 children with HAE
Dosing once every 4 weeks for children less than 6 years of age or every 2 weeks for children less than 12 years of age
Dedicated support from Takeda for patients and their caregivers
See clinical study results
Support for your child
We know that starting TAKHZYRO is a big step for your child, and we’re here to support you every step of the way. Once they’re prescribed treatment, you will receive training to ensure you know how to administer their therapy.
Do not attempt to administer TAKHZYRO to your child without first being trained by a healthcare provider. Pediatric patients (2 to less than 12 years) should not self-administer TAKHZYRO.
Explore more information about staying on track with TAKHZYRO.
Here to help
OnePath is a free product support program for eligible patients who have been prescribed a Takeda product.Get Support
Talking to your child's doctor
Get a guide to have the best conversation possible.get the guide